Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma

Oncogene

Volumn 31, Issue 44, 2012, Pages 4667-4676

  Okubo, J ^a   Takita, J ^a   Chen, Y ^a   Oki, K ^a   Nishimura, R ^a   Kato, M ^a   Sanada, M ^a   Hiwatari, M ^a   Hayashi, Y ^b   Igarashi, T ^a   Ogawa, S ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Gumna Children S Medical Center   (Japan)

Author keywords

ALK; amplification; neuroblastoma; truncated form ALK

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CARCINOGENICITY; CELL STRAIN 3T3; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXON; GENE AMPLIFICATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROBLASTOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RNA INTERFERENCE; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; GENE ORDER; HUMANS; MICE; NEUROBLASTOMA; NIH 3T3 CELLS; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SEQUENCE DELETION;

MUS MUSCULUS;

EID: 84869085945     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.616     Document Type: Article

References (37)

1. Morris SW, Kirstein MN, Valentine MB, Dittmer K, Shapiro DN, Look AT et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkinslymphoma (Vol 263, PG 1281, 1994). Science 1995; 267: 316-317.
2. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M et al. Anaplastic large-cell lymphomas expressing the novel chimeric protein P80(NPM/ALK)-a distinct clinicopathological entity. Blood 1995; 86: 1954-1960.
3. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999; 59: 2776-2780. (Pubitemid 29283106)
4. Jazii FR, Najafi Z, Malekzadeh R, Conrads TP, Ziaee AA, Abnet C et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 2006; 12: 7104-7112. (Pubitemid 44890638)
5. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-1203. (Pubitemid 350235027)
6. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-5U3.
7. Chen YY, Takita J, Choi YL, Kato M, Ohira M, Sanada M et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455: 971-U56.
8. George RE, Sanda T, Hanna M, Frohling S, Luther W, Zhang JM et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455: 975-978.
9. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455: 967-U51.
10. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-U22.
11. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-2120. (Pubitemid 46935947)
12. De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, di Montezemolo LC et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003; 21: 1592-1601. (Pubitemid 46594114)
13. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341: 1165-1173. (Pubitemid 29480654)
14. Pearson ADJ, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D et al. High-dose rapid and standard induction chemotherapy for patients aged over year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008; 9: 247-256. (Pubitemid 351722944)
15. Beckmann G, Bork P. An adhesive domain detected in functionally diverse receptors. Trends Biochem Sci 1993; 18: 40-41. (Pubitemid 23145108)
16. Loren CE, Englund C, Grabbe C, Hallberg B, Hunter T, Palmer RH. A crucial role for the anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster. EMBO Rep 2003; 4: 781-786. (Pubitemid 37063186)
17. Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PNG, Boehmer FD et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 2009; 36: 326-339.
18. Mazot P, Cazes A, Boutterin MC, Figueiredo A, Raynal V, Combaret V et al. The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking. Oncogene 2011; 30: 2017-2025.
19. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141: 1117-1134.
20. Lu Y, Yao HP, Wang MH. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett 2007; 257: 157-164. (Pubitemid 47538834)
21. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation-biological significance and potential target for anticancer therapy. Ann Oncol 2001; 12: 745-760. (Pubitemid 32655082)
22. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth-factor receptor, transforming growth factor-alpha, and epidermal growth-factor and their expression in human gliomas in vivo. Cancer Res 1991; 51: 2164-2172.
23. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS et al. Structural alterations of the epidermal growth-factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992; 89: 2965-2969.
24. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009; 16: 748-754.
25. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR et al. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 1996; 271: 25639-25645. (Pubitemid 26337944)
26. Zhou YQ, He C, Chen YQ, Wang D, Wang MH. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 2003; 22: 186-197. (Pubitemid 36174176)
27. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 1993; 8: 1195-1202. (Pubitemid 23129841)
28. Wang MH, Kurtz AL, Chen YQ. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 2000; 21: 1507-1512. (Pubitemid 30603978)
29. Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ, Wang MH. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 2000; 261: 229-238.
30. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009; 420: 345-361.
31. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11-23.
32. Schulte JH, Bachmann HS, Brockmeyer B, DePreter K, Oberthur A, Ackermann S et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res 2011; 17: 5082-5092.
33. Takita J, Yang HW, Chen YY, Hanada R, Yamamoto K, Teitz T et al. Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma. Oncogene 2001; 20: 4424-4432. (Pubitemid 32726887)
34. Brodeur GM, Pritchard J, Berthold F, Carlsen NLT, Castel V, Castleberry RP et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477. (Pubitemid 23228250)
35. Takita J, Hayashi Y, Nakajima T, Adachi J, Tanaka T, Yamaguchi N et al. The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients. Oncogene 1998; 17: 3137-3143. (Pubitemid 29020809)
36. Donella-Deana A, Marin O, Cesaro L, Gunby RH, Ferrarese A, Coluccia AML et al. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry 2005; 44: 8533-8542. (Pubitemid 40799935)
37. Smith JL, McBride CM, Nataraj PS, Bartos DC, January CT, Delisle BP. Traffickingdeficient hERG K(+) channels linked to long QT syndrome are regulated by a microtubule-dependent quality control compartment in the ER. Am J Physiol-Cell Physiol 2011; 301: C75-C85.